Form 4: Lucid Diagnostics Director Matheis Dennis Acquires Shares in Multiple Transactions

Director Matheis Dennis increased his holdings in Lucid Diagnostics through a series of purchases between May 20th and May 22nd, 2025.

Summary

• Director Dennis Matheis of Lucid Diagnostics Inc. acquired common stock in multiple transactions.
• On May 20, 2025, he purchased 187,098 shares at a weighted average price of $1.295 per share.
• On May 21, 2025, he acquired an additional 129,684 shares at a weighted average price of $1.3226 per share.
• Finally, on May 22, 2025, he bought 33,218 shares at a weighted average price of $1.3184 per share, bringing his total holdings to 350,000 shares.
• The prices for these purchases ranged from $1.265 to $1.32 per share.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a simple disclosure of stock purchases by a director. While insider buying can be seen as positive, it's not overwhelmingly so without additional context.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• Shareholders may view the director's stock purchase as a positive signal.

Key Dates

Keywords

Lucid Diagnostics, LUCD, Director, Dennis Matheis, Stock Purchase, Form 4, Beneficial Ownership